Bispecific Monoclonal Antibodies for Radioimmunotherapy
Author Information
Author(s): K. Bosslet, A. Steinstraesser, P. Hermentin, L. Kuhlmann, A. Bruynck, M. Magerstaedt, G. Seemann, A. Schwarz, H.H. Sedlacek
Primary Institution: Research Laboratories of Behringwerke AG
Hypothesis
A two-phase radioimmunotherapy using bispecific monoclonal antibodies may be more effective for treating carcinomas than current immunotherapies.
Conclusion
The study successfully generated bispecific monoclonal antibodies that can effectively target and retain in human carcinoma xenografts.
Supporting Evidence
- High avidity anti-metal chelate monoclonal antibodies were successfully generated.
- Bispecific antibodies showed significant retention in human carcinoma xenografts.
- Comparative studies indicated DTPA-Y-90 as the most stable chelate for in vivo application.
Takeaway
Scientists created special antibodies that can find and stick to cancer cells better, which might help treat cancer more effectively.
Methodology
The study involved immunohistochemical investigations, hybridoma production, and in vivo stability studies in mice.
Limitations
Epitope saturation was not achieved despite high doses of monoclonal antibodies.
Participant Demographics
Nude mice with human colon carcinoma xenografts were used in the study.
Want to read the original?
Access the complete publication on the publisher's website